Baker McKenzie Advises Novo Nordisk on the Acquisition of a Production Plant in the Czech Republic

Baker McKenzie Prague advised Novo Nordisk, a leading global healthcare company, on their acquisition of a production facility in Bohumil (Jevany), Czech Republic, from a US-based biotechnology company Novavax. This USD 200 million transaction includes a state-of-the-art recombinant protein manufacturing facility with support buildings and the transfer of more than 300 employees.

The Baker McKenzie Prague team was led by partner Tomáš Skoumal and supported by associates Jan Dudík and Michal Malkovský. Together they provided comprehensive advisory services on all legal aspects of the transaction, including due diligence and negotiation of the acquisition documents.